IP Library Granted Patent US 11,851,694
Granted Patent B1
US 11,851,694 · App. 16/794,318 · Granted Dec 26, 2023

High fidelity in vitro transcription

Inventors: David Mauger (Arlington, MA); Vladimir Presnyak (Manchester, NH); Amy E. Rabideau (Waltham, MA); Iain Mcfadyen (Arlington, MA)
Assignee: ModernaTX, Inc.
C12P19/34C12N15/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,851,694
App. No.
16/794,318
Granted
Dec 26, 2023
Kind
B1
Abstract

The present disclosure provides methods and compositions for high fidelity in vitro transcription reactions.

Claims (24)

1. A method of producing a messenger RNA (mRNA), the method comprising

(a) identifying a non-canonical terminator motif NNATCTGTTNN (SEQ ID NO: 50) in a DNA encoding a mRNA that encodes a polypeptide, wherein N at each position of the non-canonical terminator motif is any nucleotide selected from A, T, C, and G;

(b) producing a modified DNA comprising at least one codon substitution in the non-canonical terminator motif that preserves the amino acid sequence of the polypeptide; and

(c) producing a modified mRNA in an in vitro transcription reaction that comprises the modified DNA, nucleoside triphosphates, and a T7 RNA polymerase.

2. The method of claim 1 , wherein:

the polypeptide comprises an amino acid sequence X1-Ser-Val, and X1 is selected from the group consisting of Ile, Leu, Val, Ala, Gly, Pro, Thr, Ser, Gln, Glu, Lys, and Arg;

the polypeptide comprises an amino acid sequence X2-Leu-Phe, and X2 is selected from the group consisting of Tyr, His, Asn, and Asp;

the polypeptide comprises an amino acid sequence X2-Leu-Leu, and X2 is selected from the group consisting of Tyr, His, Asn, and Asp;

the polypeptide comprises an amino acid sequence Ile-Cys-X3, and X3 is selected from the group consisting of Leu, Phe, Cys, Ser, Tyr, and Trp.

3. The method of claim 1 , wherein the T7 RNA polymerase comprises the amino acid sequence of SEQ ID NO: 1.

4. The method of claim 1 , wherein the T7 RNA polymerase comprises an amino acid substitution at position 47, relative to a T7 RNA polymerase comprising the amino acid sequence of SEQ ID NO: 1.

5. The method of claim 4 , wherein the amino acid substitution at position 47 is G47A.

6. The method of claim 5 , wherein the amino acid modification comprises an additional C-terminal amino acid, relative to the T7 RNA polymerase comprising the amino acid sequence of SEQ ID NO: 1.

7. The method of claim 6 , wherein the additional C-terminal amino acid is selected from glycine, threonine, serine, alanine, and proline.

8. The method of claim 1 , wherein the T7 RNA polymerase comprises an amino acid substitution at a position selected from positions 350, 351, 387, 394, 425, 427, 437, 441, 632, 811, and 880, relative to T7 RNA polymerase comprising the amino acid sequence of SEQ ID NO: 1.

9. The method of claim 8 , wherein the amino acid substitution is at position 350, and the amino acid substitution at position 350 is selected from E350K, E350N, E350A, and E350W.

10. A method of producing a modified DNA encoding a messenger RNA (mRNA), the method comprising

(a) identifying a non-canonical terminator motif NNATCTGTTNN (SEQ ID NO: 50) in a DNA encoding a mRNA that encodes a polypeptide, wherein N at each position of the non-canonical terminator motif is any nucleotide selected from A, T, C, and G; and

(b) producing a modified DNA encoding the mRNA, wherein the modified DNA comprises at least one codon substitution in the non-canonical terminator motif that preserves the amino acid sequence of the polypeptide encoded by the mRNA.

11. The method of claim 8 , wherein the amino acid substitution is at position 351, and the amino acid substitution at position 351 is D351V.

12. The method of claim 8 , wherein the amino acid substitution is at position 387, and the amino acid substitution at position 387 is K387H, K387N, and K387S.

13. The method of claim 8 , wherein the amino acid substitution is at position 437, and the amino acid substitution at position 437 is N437T, N437I, N437Y and N437F.

14. The method of claim 8 , wherein the amino acid substitution is at position 441, and the amino acid substitution at position 441 is K441R.

15. The method of claim 8 , wherein the amino acid substitution is at position 880, and the amino acid substitution at position 880 is F880Y.

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2022
From: MAUGER, DAVID; PRESNYAK, VLADIMIR; RABIDEAU, AMY E.; MCFADYEN, IAIN
To: MODERNATX, INC.
Reel/Frame 061336/0007 →
Cited By (13)
US 12,383,508 US 12,403,335 US 12,403,336 US 12,409,218 US 12,409,347 US 12,428,577 US 12,453,766 US 12,460,259 US 12,521,577 US 12,551,734 US 12,582,609 US 12,622,960 US 12,629,412